Journal of Rare Cardiovascular Diseases 2022; 4(5): 204–209
www.jrcd.eu

Review Article

# Cardiovascular Diseases: Insights into Recent Research and Emerging Perspectives

**Heba A. Abd-Alsalam Alsalame[1,2], Ihsan Khudhair Jasim[3], Sarah Ghazi Abdulkarim Alzorri[4], Hadeel Mizher Younis[5], Hiatham Younis Mohammed[5], Mohammed Ahmed Mustafa[6] and Vivek Kumar Pandey[7,*]**
[1]Department of Biology, College of Education for Pure Science, University of Kerbala, Kerbala, Iraq
[2]Department of Medical Laboratory Technology, Al-Zahrawi University College, Karbala, Iraq
[3]College of Pharmacy, Al-Turath University, Baghdad, Iraq
[4]Department of Laboratory Techniques, College of Medical Techniques, Al-Farahidi University, Iraq, Baghdad
[5]Department of Microbiology, College of Veterinary Medicine, University of Tikrit, Iraq
[6]Department of Biology, College of Education, University of Samarra, Samarra, Iraq
[7]Centre for Research Impact & Outcome, Chitkara University Institute of Engineering and Technology, Chitkara University, Rajpura, 140401, Punjab, India

E-mail: vivek_pandey1@outlook.com .

Recevied: 21 October 2024, Accept: 15 December 2024, Published: 31 December 2024

## Abstract

Cardiovascular diseases (CVDs) remain a leading cause of mortality worldwide, encompassing conditions like coronary artery disease, heart failure, and peripheral vascular disorders. Recent advances in materials science, nanotechnology, and pharmacology have provided novel insights into understanding and managing these conditions. This review integrates findings from diverse research areas, highlighting innovative approaches like nanoparticle-based drug delivery, 3D printing in medical applications, and biochemical insights into heart muscle pathology. A multidisciplinary approach is crucial for advancing therapeutic strategies and improving patient outcomes.

**Keywords:** cardiovascular diseases,nanotechnology, 3D printing,heart muscle pathology,nanoparticles,advanced materials

## 1. Introduction

Cardiovascular diseases (CVDs) pose a significant health challenge globally, demanding innovative solutions from diverse scientific disciplines [1]. Traditional approaches to managing CVDs have been complemented by groundbreaking advancements in materials science, pharmacology, and bioengineering [2]. This review synthesizes recent studies, emphasizing their relevance to CVD diagnosis, treatment, and prevention. The studies covered include investigations into the biochemical impact of oncology drugs on heart muscle, the role of advanced 3D printing materials [3]. in medical applications, and the potential of nanotechnology in therapeutic interventions. Together, these findings underline the importance of interdisciplinary collaboration in add Cardiovascular diseases (CVDs) remain the leading cause of death worldwide, accounting for a substantial share of global mortality and morbidity. Despite significant advancements in prevention and treatment, the burden of CVDs continues to rise, fueled by an aging population, urbanization, and increasing prevalence of lifestyle-related risk factors such as obesity, diabetes, and hypertension. This growing health crisis underscores the importance of research and innovation in understanding, diagnosing, and managing cardiovascular conditions [4].

Recent research has focused on unraveling the complex mechanisms underlying CVDs, including genetic predispositions, molecular pathways, and inflammatory processes. Simultaneously, advancements in diagnostic technologies, such as cardiac imaging and biomarker discovery, have improved early detection and risk stratification. Emerging therapeutic approaches, including regenerative medicine, gene therapy, and personalized medicine, offer promising avenues for more targeted and effective treatments [5].

This paper explores the latest developments in cardiovascular research and highlights emerging perspectives that aim to address the global burden of CVDs. By examining innovative diagnostic techniques, novel therapeutic strategies, and preventive measures, it seeks to provide a comprehensive overview of how scientific progress is shaping the future of cardiovascular health.

Through a deeper understanding of these advancements, we can move closer to mitigating the impact of CVDs and improving outcomes for patients worldwide [6].

### 1.1. Introduction to cardiovascular diseases

Cardiovascular diseases (CVDs) are the leading cause of morbidity and mortality worldwide, posing a significant burden on global health systems. They encompass a wide range of conditions affecting the heart and blood vessels, including coronary artery disease, heart failure, and stroke. CVDs account for nearly 18 million deaths annually, representing approximately 32% of all global deaths, with the majority resulting from ischemic heart disease and cerebrovascular events [7].

### 1.2. Global burden of cardiovascular diseases

- CVDs are prevalent across all regions, but low- and middle-income countries bear the brunt of the burden, accounting for over 75% of CVD-related deaths. This disparity is largely due to limited access to healthcare, late diagnosis, and inadequate management [8].
- The increasing prevalence of risk factors, such as obesity, diabetes, hypertension, and sedentary lifestyles, has further exacerbated the global CVD epidemic [9].

### 1.3. Impact on public health

- **Economic Costs:** CVDs impose significant economic strain on healthcare systems and economies worldwide. Direct costs include medical treatment and hospitalizations, while indirect costs arise from lost productivity due to disability and premature death [4].
- **Quality of Life:** CVDs often lead to chronic disability, reducing the quality of life for millions of individuals. Conditions like heart failure and post-stroke impairments require long-term care and rehabilitation, placing additional burdens on families and caregivers [10].

### 1.4. Key risk factors

The development of CVDs is influenced by both modifiable and non-modifiable risk factors:

- **Modifiable Risk Factors:**
  - Unhealthy diets, high in saturated fats, salt, and sugar [11].
  - Physical inactivity and sedentary lifestyles [12].
  - Tobacco use and excessive alcohol consumption [13].
  - Poorly controlled hypertension, diabetes, and hyperlipidemia [14].
- **Non-Modifiable Risk Factors:**
  - Age and gender, with older individuals and men at higher risk [10].
  - Genetic predispositions and family history of cardiovascular diseases [11].

### 1.5. Global efforts to address CVDs

- **Prevention Programs:** Global initiatives, such as the WHO's Global Hearts Program, aim to reduce CVD-related deaths through lifestyle interventions, improved access to medications, and public awareness campaigns [15].
- **Technological Advancements:** Innovations in diagnostics, personalized medicine, and minimally invasive treatments have significantly improved the management and outcomes of CVDs.

## 2. Advances in Understanding Pathophysiology

The field of cardiovascular research has made remarkable strides in uncovering the complex pathophysiological mechanisms underlying cardiovascular diseases (CVDs). These advancements have provided deeper insights into the molecular, genetic, and cellular processes driving the development and progression of these conditions, paving the way for innovative diagnostic and therapeutic approaches [15].

### 2.1. Role of inflammation and immune dysregulation

Recent studies have highlighted the critical role of inflammation and immune dysregulation in the pathogenesis of CVDs.

- **Chronic Inflammation:** Inflammatory pathways, such as those mediated by interleukin-1 (IL-1) and tumor necrosis factor-alpha (TNF-$\alpha$), contribute to endothelial dysfunction, plaque formation, and progression of atherosclerosis [16].
- **Immune Responses:** Emerging evidence suggests that adaptive and innate immune responses, including the role of T-cells and macrophages, are pivotal in the destabilization of atherosclerotic plaques and myocardial injury [17].

### 2.2. Genetic and epigenetic mechanisms

- **Genetic Insights:** Advances in genome-wide association studies (GWAS) have identified multiple genetic variants associated with CVD risk, providing insights into predispositions and potential therapeutic targets [18].
- **Epigenetic Modifications:** Epigenetic changes, such as DNA methylation and histone modifications, influence gene expression related to vascular inflammation and myocardial remodeling, offering new avenues for precision medicine [19].

### 2.3. Oxidative stress and endothelial dysfunction

- **Reactive Oxygen Species (ROS):** Excessive ROS production contributes to oxidative stress, leading to damage of endothelial cells and vascular smooth muscle cells, which are key events in the development of hypertension and atherosclerosis [20].

- **Endothelial Dysfunction:** Impaired nitric oxide (NO) signaling and increased oxidative stress disrupt vascular homeostasis, triggering vasoconstriction, inflammation, and thrombosis [21].

## 2.4. Advances in understanding heart failure pathophysiology

- **Neurohormonal Activation:** Insights into the renin-angiotensin-aldosterone system (RAAS) and sympathetic nervous system have deepened understanding of their role in heart failure progression and management [22].
- **Cardiac Fibrosis:** Research on myocardial fibrosis has shed light on its contribution to stiffening of the heart muscle and impaired contractility in heart failure with preserved ejection fraction (HFpEF).

Innovations in Diagnostic Techniques Advances in diagnostic technologies have transformed the landscape of cardiovascular medicine, enabling earlier detection, more accurate risk stratification, and personalized management of cardiovascular diseases (CVDs). These innovations, including cardiac magnetic resonance imaging (CMR) and genetic testing, have enhanced the ability to diagnose complex conditions and predict disease progression [23].

## 2.5. Cardiac magnetic resonance imaging (CMR)

CMR has emerged as a gold-standard tool for assessing cardiac structure, function, and tissue characterization.

- **High-Resolution Imaging:** CMR provides unparalleled clarity in visualizing myocardial architecture, including detailed assessment of wall motion, ventricular volumes, and ejection fraction [24].
- **Tissue Characterization:** Techniques like late gadolinium enhancement (LGE) detect myocardial fibrosis and scarring, offering critical insights into conditions such as hypertrophic cardiomyopathy and myocarditis [25].
- **Stress Testing:** Stress CMR combines functional imaging with pharmacological stress agents to evaluate ischemic heart disease, improving diagnostic accuracy compared to traditional stress tests [26].

## 2.6. Genetic testing in cardiovascular diseases

Genetic testing has become a cornerstone in the diagnosis and management of hereditary cardiovascular conditions.

- **Identifying Genetic Mutations:** Tests for conditions like hypertrophic cardiomyopathy, long QT syndrome, and familial hypercholesterolemia help pinpoint mutations in genes associated with these disorders [27].
- **Risk Stratification:** Genetic screening in asymptomatic family members of affected individuals enables early detection and preventive interventions, reducing the likelihood of adverse outcomes [28].
- **Polygenic Risk Scores:** These scores aggregate multiple genetic variants to provide a comprehensive risk assessment for common conditions like coronary artery disease, facilitating personalized prevention strategies [29].

## 2.7. Integration of artificial intelligence (AI) in diagnostics

AI-driven algorithms are increasingly being integrated into diagnostic workflows to enhance accuracy and efficiency.

- **Automated Image Analysis:** AI tools improve the interpretation of CMR and echocardiography by identifying subtle abnormalities that may be missed by human observers.
- **Predictive Analytics:** AI models use data from imaging, genetic testing, and clinical parameters to predict disease progression and guide treatment decisions [30].

Emerging Therapeutic Approaches The treatment landscape for cardiovascular diseases (CVDs) is rapidly evolving, with innovative therapies aiming to address unmet needs and improve patient outcomes. Recent advancements, such as novel pharmacological agents and gene therapy, represent significant strides toward more effective and personalized cardiovascular care [30].

## 2.8. Novel pharmacological agents

- **Sodium-Glucose Co-Transporter 2 (SGLT2) Inhibitors:** Originally developed for diabetes, drugs like dapagliflozin and empagliflozin have demonstrated cardioprotective effects. They reduce heart failure hospitalizations and improve survival in patients with heart failure, regardless of diabetes status [31].
- **Angiotensin Receptor-Neprilysin Inhibitors (ARNIs):** Sacubitril/valsartan has redefined heart failure treatment by combining neprilysin inhibition with angiotensin receptor blockade, leading to reduced mortality and better symptom management in patients with reduced ejection fraction [32].
- **PCSK9 Inhibitors:** These monoclonal antibodies, such as evolocumab and alirocumab, significantly lower LDL cholesterol levels, reducing the risk of atherosclerotic cardiovascular events in high-risk patients [33].
- **Anti-Inflammatory Therapies:** Targeting inflammation has become a new frontier in CVD treatment. The CANTOS trial highlighted the potential of

canakinumab, an IL-1$\beta$ inhibitor, in reducing recurrent cardiovascular events in patients with residual inflammatory risk [34].

### 2.9. Gene therapy

- **Addressing Monogenic Disorders:** Gene therapy is making strides in treating inherited cardiovascular conditions such as familial hypercholesterolemia and hypertrophic cardiomyopathy. Techniques like CRISPR/Cas9 and viral vector-based delivery systems are being developed to correct genetic mutations at their source [35].
- **Angiogenesis Stimulation:** Gene-based therapies aim to stimulate angiogenesis in ischemic tissues by delivering genes encoding angiogenic growth factors such as VEGF and FGF, providing new treatment options for patients with refractory angina or critical limb ischemia [36].
- **RNA-Based Therapies:** Advances in RNA interference (RNAi) and antisense oligonucleotides (ASOs) are enabling the silencing of genes that contribute to cardiovascular pathologies, such as those involved in lipid metabolism and arrhythmias [37].

### 2.10. Regenerative Medicine

- **Stem Cell Therapy:** Mesenchymal stem cells (MSCs) and induced pluripotent stem cells (iPSCs) are being explored for their potential to regenerate damaged myocardium and improve cardiac function in heart failure patients [38].
- **Exosome-Based Therapies:** Exosomes derived from stem cells are being investigated for their ability to deliver reparative signals to damaged cardiac tissue, offering a cell-free approach to regenerative therapy [39].

### 2.11. Artificial intelligence in drug development

AI and machine learning are being increasingly utilized in drug discovery, accelerating the identification of novel therapeutic targets and optimizing clinical trial designs. These technologies have the potential to bring innovative treatments to market more efficiently [40].

### 2.12. Role of lifestyle and preventive strategies

Lifestyle modifications are central to preventing cardiovascular diseases (CVDs) and enhancing treatment outcomes. Addressing modifiable risk factors, such as poor diet, physical inactivity, and smoking, can significantly reduce the incidence and severity of CVDs [41].

### 2.13. Dietary modifications

- *Heart-Healthy Diets:* Diets like the Mediterranean and DASH (Dietary Approaches to Stop Hypertension) have been proven to lower blood pressure, reduce cholesterol levels, and improve overall cardiovascular health [42].
- *Salt and Sugar Reduction:* Limiting sodium and added sugars helps prevent hypertension and obesity, two major contributors to CVDs [43].

### 2.14. Physical activity

- **Regular Exercise:** Moderate-intensity aerobic exercise, such as walking or cycling, for at least 150 minutes per week, improves cardiac function, reduces inflammation, and aids weight management [44].

### 2.15. Smoking cessation and alcohol moderation

- Quitting smoking and limiting alcohol intake are critical preventive measures that reduce the risk of atherosclerosis, myocardial infarction, and stroke [45].

### 2.16. Stress management and sleep hygiene

- Chronic stress and poor sleep quality exacerbate cardiovascular risk. Techniques like mindfulness, yoga, and maintaining a consistent sleep schedule contribute to heart health [46].

### 2.17. Impact of artificial intelligence and big data in cardiovascular medicine

Artificial intelligence (AI) and big data are revolutionizing cardiovascular care by enhancing diagnostic accuracy, optimizing treatment strategies, and improving patient outcomes [47].

## 3. Predictive Analytics

- AI-driven algorithms analyze electronic health records and imaging data to identify patients at high risk for CVDs, enabling early intervention [48].

### 3.1. Advanced diagnostics

- **AI in Imaging:** Tools such as deep learning enhance the interpretation of cardiac imaging modalities, including echocardiograms, MRIs, and CT scans, detecting abnormalities with precision [49].
- **Wearable Devices:** AI-powered wearables, like smartwatches, monitor vital signs and detect arrhythmias, such as atrial fibrillation, in real-time.

### 3.2. Personalized treatment

- AI facilitates the development of individualized treatment plans by analyzing patient-specific data, including genetics, lifestyle factors, and comorbidities.

### 3.3. Enhanced clinical decision-making

- Big data integration supports clinicians in choosing optimal therapies, predicting outcomes, and monitoring disease progression more effectively [50].

### 3.4. Cardiovascular diseases in low-resource settings

Managing CVDs in low-resource settings poses unique challenges but also presents opportunities for innovative solutions to bridge the gap in care [41].

### 3.5. Challenges

- **Limited Healthcare Infrastructure:** A shortage of specialized healthcare facilities, trained personnel, and advanced equipment hinders timely diagnosis and treatment [42].
- **Economic Barriers:** High costs of medications and treatments make CVD care inaccessible to many [43].
- **Awareness Deficits:** Low health literacy and limited awareness about CVD risk factors lead to late presentations and poor outcomes [44].

### 3.6. Opportunities for improvement

- **Community-Based Interventions:** Educating communities about lifestyle modifications and early signs of CVD can promote prevention and early detection [45].
- **Telemedicine and Mobile Health:** Leveraging digital health solutions allows for remote monitoring, consultations, and education in underserved areas [46].
- **Low-Cost Diagnostic Tools:** Innovations such as portable ECG devices and point-of-care testing provide affordable options for early diagnosis.

### 3.7. Global collaborations and funding

- International partnerships and increased funding can support training programs, infrastructure development, and affordable access to essential medications and diagnostics.

## 4. Conclusion

Recent advancements in cardiovascular research demonstrate the transformative potential of integrating nanotechnology, 3D printing, and natural product-based pharmacology. These innovations not only improve therapeutic efficacy but also enhance patient safety and quality of life. Continued interdisciplinary collaboration is critical to overcoming the challenges posed by CVDs and achieving long-term health outcomes.

## References

[1] Libby, Peter, et al. "Inflammation in atherosclerosis: from pathophysiology to practice."*Journal of the American College of Cardiology* 54.23 (2009): 2129-2138.

[2] Hansson, Göran K. "Inflammation, atherosclerosis, and coronary artery disease." *New England Journal of Medicine* 352.16 (2005): 1685-1695.

[3] Swirski, Filip K., and Matthias Nahrendorf. "Macrophage-stem cell crosstalk after myocardial infarction." *Journal of the American College of Cardiology* 62.20 (2013): 1902-1904.

[4] Maddox, Thomas M., et al. "The learning healthcare system and cardiovascular care: a scientific statement from the American Heart Association." *Circulation 135*.14 (2017): e826-e857.

[5] Madamanchi, Nageswara R., Aleksandr Vendrov, and Marschall S. Runge. "Oxidative stress and vascular disease." *Arteriosclerosis, Thrombosis, and Vascular Biology* 25.1 (2005): 29-38.

[6] Griendling, Kathy K., and Garret A. FitzGerald. "Oxidative stress and cardiovascular injury: Part I: basic mechanisms and in vivo monitoring of ROS." *Circulation* 108.16 (2003): 1912-1916.

[7] Paulus, Walter J., and Carsten Tschöpe. "A novel paradigm for heart failure with preserved ejection fraction: comorbidities drive myocardial dysfunction and remodeling through coronary microvascular endothelial inflammation." *Journal of the American College of Cardiology* 62.4 (2013): 263-271.

[8] Hajifathalian, Kaveh, et al. "A novel risk score to predict cardiovascular disease risk in national populations (Globorisk): a pooled analysis of prospective cohorts and health examination surveys." *The lancet Diabetes & endocrinology* 3.5 (2015): 339-355.

[9] Estruch, Ramón, et al. "Primary prevention of cardiovascular disease with a Mediterranean diet." *New England Journal of Medicine* 368.14 (2013): 1279-1290.

[10] Joseph, Philip, et al. "The evolution of $\beta$-blockers in coronary artery disease and heart failure (part 1/5)." *Journal of the American College of Cardiology 74*.5 (2019): 672-682.

[11] Verma, Bharat. "Exercise and Cardiovascular Health." *International Journal of Research Pedagogy and Technology in Education and Movement ScienceS* 5.02 (2016).

[12] Mills, Edward J., et al. "Cardiovascular events associated with smoking cessation pharmacotherapies: a network meta-analysis." *Circulation* 129.1 (2014): 28-41.

[13] Wang, Yun-He, et al. "Association of longitudinal patterns of habitual sleep duration with risk of cardiovascular events and all-cause mortality." *JAMA Network Open* 3.5 (2020): e205246-e205246.

[14] Johnson, Kipp W., et al. "Artificial intelligence in cardiology." *Journal of the American College of Cardiology* 71.23 (2018): 2668-2679.

[15] Gulshan, Varun, et al. "Development and validation of a deep learning algorithm for detection of diabetic retinopathy in retinal fundus photographs." *Jama* 316.22 (2016): 2402-2410.

[16] Sau, Arunashis, et al. "Artificial intelligence-enabled electrocardiogram for mortality and cardiovascular risk estimation: a model development and validation study." *The Lancet Digital Health* 6.11 (2024): e791-e802.

[17] Gaziano, Thomas, et al. "Cardiovascular disease screening by community health workers can be cost-effective in low-resource countries." *Health Affairs* 34.9 (2015): 1538-1545.

[18] Chaitanya, M. Krishna, et al. "Artificial intelligence based approach for categorization of COVID-19 ECG images in presence of other cardiovascular disorders." *Biomedical Physics & Engineering Express* 9.3 (2023): 035012.

[19] Kadhum, Hussam H., et al. "Potential pharmaceutical applications and molecular docking study for green fabricated ZnO nanoparticles mediated Raphanus sativus: In vitro and in vivo study." *Nanotechnology Reviews* 13.1 (2024): 20240113.

[20] Kamil, Rasha Ali, et al. "Improvement of the mechanical properties of polymer-modified concrete by using PC superplasticizer." *Pollack Periodica* 18.3 (2023): 14-19.

[21] Karim, Kamaran Khattab, and Nazim Rasul Abdulla. "Use of various sources of calcium in the diets of broiler and its effects on carcass and some meat quality." *Tikrit Journal for Agricultural Sciences* 24.1 (2024): 45-56.

[22] Kashkool, Marwah Jaafar, et al. "Some Mechanical Properties of Polymer Modified Concrete by Adding Waste Iron Filings and Chips." *Key Engineering Materials* 895 (2021): 110-120.

[23] Mahmood, Adnan, et al. "The Efficacy of Quinolones and Fluoroquinolones in the Medicine: a review study." *Iraqi Journal of Medical and Health Sciences* 1.1 (2024): 27-35.

[24] Mejía, Nora, et al. "Potential of Nanocages as Effective Catalysts for Oxygen Reduction Reaction." *Silicon* (2024): 1-8.

[25] Abdulazeez, Maha Isam, et al. "Dental trauma of permanent incisor teeth in children/Kirkuk city." *Systematic Reviews in Pharmacy* 11.12 (2020).

[26] Abdullah, Khalida Khalil, et al. "A comparative study of effect of Cymbopogon citrates aqueous extract and rosuvastatin on experimentally induced hyperlipidemia in local rabbits." *AIP Conference Proceedings.* Vol. 2394. No. 1. AIP Publishing, 2022.

[27] Abdulnabi, O. W., H. A. Alsalame, and M. N. Al-baiati. "Studying of Using Chitosan-Cephalexin Nano composed to Induce ROS and Apoptosis in Colon Cancer Cell Line HCT-29." *Moroccan Journal of Chemistry* 12.3 (2024): 1270-1280.

[28] Abdulqader, Abeer T., Aseel Muthana Yousif Al-Sammarie, and Mohammed Ahmed Mustafa. "A comparative environmental study of aqueous extracts of ginger and grapes to protect hepatocytes in Albino rabbits and a comparison of extracts in preserving Awassi lamb meat from oxidation." IOP Conference Series: Earth and Environmental Science. Vol. 1029. No. 1. IOP Publishing, 2022.

[29] Al-Omairi, Baida Ajeal Badir, and Len Nokes. "The Impact of Twisting on The Extent of Lower Lumbar Spine Lateral Flexion Among Healthy Subjects." *Iraqi Journal of Medical and Health Sciences* 1.1 (2024): 22-26.

[30] AL-Aameli, Muna Hussain, Rajaa Ali Moheiseen Al-Taee, and H. A. Alsalame. "Histological & physiological alternations in the aorta & heart in relation with cholesterol diet in male albino rat." *Indian J. Forensic Med.* Toxicol 13 (2019): 313-318.

[31] Alabbasy, Raghad Hazem, et al. "Histological study of the effect of some oncology drugs on heart muscle." *AIP Conference Proceedings.* Vol. 2977. No. 1. AIP Publishing, 2023.

[32] Al-Abodi, Hiba Riyadh, et al. "Novel gold nanobiosensor platforms for rapid and inexpensive detection of Vibrio cholerae." *Reviews and Research in Medical Microbiology* 31.2 (2020): 70-74.

[33] Al-Bahrani, Hussein S., et al. "Determining new way to detect hydrocarbon polluted water at vertical and horizontal spaces." *Materials Today: Proceedings* 42 (2021): 2071-2075.

[34] Ali, Raghad Hassan, et al. "Assessment of Serum Cystatin C and Apolipoprotein Levels in Chronic Kidney Disease Patients." *Iraqi Journal of Medical and Health Sciences* 1.1 (2024): 8-13.

[35] AL-qanbar, Mohammed Majid, Wefak Jbori AL-Bazi, and Hepa A. Abd-Alsalam. "The effect of Hyperhomocysteinemia on the Osteoclasts activity in Male New Zealand White Rabbits." *Research Journal of Pharmacy and Technology* 15.12 (2022): 5443-5448.

[36] Al-Salam, Yasser, Mohammed J. Mohammed, and Hani Sabbar Ayed. "Effect of Molecular Substitution of Oats and Chia Powder for Animal Fats on Chemical Indicators and Physical Properties in the Manufacture of Freeze-Preserved Beef Burgers." *Tikrit Journal for Agricultural Sciences* 24.1 (2024): 170-179.

[37] Al-Salam, Yasser, Mohammed J. Mohammed, and Hani Sabbar Ayed. "Effect of Molecular Substitution of Oats and Chia Powder for Animal Fats on Chemical Indicators and Physical Properties in the Manufacture of Freeze-Preserved Beef Burgers." *Tikrit Journal for Agricultural Sciences* 24.1 (2024): 170-179.

[38] Hama Hasan, Torken Ahmed, et al. "Effect of Equisetum Arvense Phenolic Extract in Treatment of Entamoeba Histolytica Infection." *Systematic Reviews in Pharmacy* 11.11 (2020).

[39] Hsu, Chou-Yi, et al. "Amphiregulin in infectious diseases: Role, mechanism, and potential therapeutic targets." *Microbial Pathogenesis* 186 (2024): 106463.

[40] Hsu, Chou-Yi, et al. "Exploiting the immune system in hepatic tumor targeting: unleashing the potential of drugs, natural products, and nanoparticles." *Pathology-Research and Practice* (2024): 155266.

[41] Jalal, Bnar J., and Mustafa RM Alqaisi. "Improving the production and quality of white button mushroom (Agaricus bisporus) by adding biochar and ash to the casing layer." *Tikrit Journal for Agricultural Sciences* 24.1 (2024): 22-33.

[42] Jawad, Zainab Nizar. "The Association of Urokinase Gene 3'-Utr T/c Polymorphism With Urinary Bladder Cancer." *Biochemical & Cellular Archives* 18.1 (2018).

[43] Jawad, Zainab Nizar. "Molecular Diagnosis of CD14 and MnSOD Genes and their Effect on Asthma in Holy Karbala, Iraq." *Indian Journal of Public Health Research & Development* 10.8 (2019).

[44] Jawad, Zainab Nizar. "Molecular detection of caspase 3, 8, 9 genes and ADIPOR1 (rs2275738) polymorphism in colorectal cancer." *Applied Nanoscience* 13.8 (2023): 5365-5368.

[45] Jawad, Zainab Nizar. "Association between APC gene SNPs and the risk of occurrence of colorectal cancer." *AIP Conference Proceedings.* Vol. 2414. No. 1. AIP Publishing, 2023.

[46] Jawad, Zainab Nizar, and Kamal AR. "Association of Additive Risk of Pioglitazone Use with the Presence of CYP1A1 Polymorphisms in the Occurrence of Bladder Cancer." *Systematic Reviews in Pharmacy* 11.5 (2020).

[47] Jawad, Zainab Nizar, and Weaam Awad. "Association of urokinase and Vitamin D receptor genes SNPs and urolithiasis in an Iraqi population." *Meta Gene* 24 (2020): 100679.

[48] Alsalame, Heba A. Abd-Alsalam. "Study the Effect of Lycium barbarum Polysaccharide on Bone and Thyroid Gland in Hyperlipidemic Healthy Male Albino Rats." *Scopus Ijphrd Citation Score* 10.7 (2019): 764.

[49] Alsalame, Heba A. Abd-Alsalam. "Study Effects of Nigella Sativa Seeds Oil in Some Physiological Parameters in Experimental Heart Failure Induced by Ivabradine in Male Rats." *Indian Journal of Forensic Medicine & Toxicology* 14.3 (2020): 2609-2613.

[50] Alsalame, Heba A. Abd-Alsalam, and Layla S. Laylani. "Evolution the effectiveness of Vernonia amygdalina in some physiological parameters against hepatic and renal injury in male rats: Evaluating the Efficacy of Vernonia amygdalina on Physiological Parameters in Ameliorating Hepatic and Renal Injury in Male Rats." *Tikrit Journal for Agricultural Sciences* 24.2 (2024): 298-310.